Originally published by our sister publication Clinical Oncology News
By Clinical Oncology News Staff
The FDA has approved tislelizumab-jsgr (Tevimbra, BeiGene), in combination with platinum and fluoropyrimidine-based chemotherapy, for the first-line treatment of unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma (G/GEJ) cancers in adults whose tumors express PD-L1 (programmed death ligand-1) (≥1).
The additional indication for first-line G/GEJ cancers